Details for Patent: 9,657,003

Which drugs does patent 9,657,003 protect, and when does it expire?

Patent 9,657,003 protects NUBEQA and is included in one NDA.

This patent has ninety-four patent family members in thirty-six countries.

Summary for Patent: 9,657,003

Title:	Androgen receptor modulating compounds
Abstract:	The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
Inventor(s):	Wohlfahrt; Gerd (Helsinki, FI), Tormakangas; Olli (Turku, FI), Salo; Harri (Turku, FI), Hoglund; Iisa (Turku, FI), Karjalainen; Arja (Espoo, FI), Koivikko; Pia (Littoinen, FI), Holm; Patrik (Lielahti TL, FI), Rasku; Sirpa (Vantaa, FI), Vesalainen; Anniina (Paimio, FI)
Assignee:	ORION CORPORATION (FI)
Application Number:	14/598,973
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,657,003

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y	Y		TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

International Family Members for US Patent 9,657,003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	078793
Australia	2007213960
Australia	2010311299